Next Capital Management LLC Sells 2,972 Shares of Pfizer Inc. (NYSE:PFE)

Next Capital Management LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 18.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,243 shares of the biopharmaceutical company’s stock after selling 2,972 shares during the period. Next Capital Management LLC’s holdings in Pfizer were worth $351,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter valued at $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the fourth quarter valued at $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

PFE has been the topic of several recent research reports. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday. Finally, Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Up 1.0 %

Shares of NYSE PFE opened at $26.31 on Wednesday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market cap of $149.09 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The business has a fifty day simple moving average of $26.21 and a two-hundred day simple moving average of $27.09. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm posted $0.10 earnings per share. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.